Logo

Janssen (J&J) Reports Results of Erleada (apalutamide) in P-III TITAN Study for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) #ASCO2019

Share this

Janssen (J&J) Reports Results of Erleada (apalutamide) in P-III TITAN Study for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) #ASCO2019

Shots:

  • The P-III TITAN study involves assessing of Erleada + Androgen Deprivation Therapy (ADT) vs PBO + ADT in 1050 patients in ratio 1:1 with mCSPC across 23 countries
  • The P-III study results: @22.7 mos. OS (82% vs 74%); PSA (68% vs 29%); 52% reduction in risk of radiographic progression; 61% reduction in time to cytotoxic CT; 34% reduction in PFS2
  • Erleada (apalutamide) is an androgen receptor (AR) inhibitor and has received FDA approval for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) on 14 Feb-2018. The results of P-III TITAN study will accelerate the approval of Erleada for mCSPC

Click Here

Ref: Janssen | Image: Janssen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions